Bionical Emas is the only Contract Research Organization (CRO) to combine Clinical Development, Clinical Trial Supply (CTS) and Early Access Programs (EAP) bringing life-changing medicines to patients around the world.
Their unique integrated business model, with its range of services and capabilities, benefit many of the world’s leading pharma and biotech companies. This distinctive offering enables them to maximize access and generate evidence at every stage of the drug development pathway. Bionical Emas has extensive experience across all phases of clinical research, with a history in rare disease, oncology/heme-oncology and infectious diseases.
The company has an established global footprint across the US, EU and Australasia markets and has over 200 employees based around the globe, supporting many thousands of patients.
The Bionical Emas vision is to maximize access and generate evidence across the entire clinical development pathway, positively impacting current and future patients.